Safety of the Geneva Cocktail, a Cytochrome P450 and P-Glycoprotein Phenotyping Cocktail, in Healthy Volunteers from Three Different Geographic Origins.


Journal

Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928

Informations de publication

Date de publication:
11 2020
Historique:
pubmed: 28 8 2020
medline: 15 9 2021
entrez: 28 8 2020
Statut: ppublish

Résumé

INTRODUCTION AND OBJECTIVE: Cytochrome P450 enzymes are the major drug-metabolizing enzymes in humans and the importance of drug transport proteins, in particular P-glycoprotein, in the variability of drug response has also been highlighted. Activity of cytochrome P450 enzymes and P-glycoprotein can vary widely between individuals and genotyping and/or phenotyping can help assess their activity. Several phenotyping cocktails have been developed. The Geneva cocktail is composed of a specific probe for six different cytochrome P450 enzymes and one for P-glycoprotein and was used in the context of a research aiming at exploring genotypes and phenotypes in distinct human populations (NCT02789527). The aim of the present study is to solely report the safety results of the Geneva cocktail in the healthy volunteers of these populations. The Geneva cocktail is composed of caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, midazolam, and fexofenadine. The volunteers fasted and avoided drinking caffeine-containing beverages or food and grapefruit juice overnight before receiving the cocktail orally. They provided blood spots for the probes' concentrations at 2, 3, and 6 h after ingestion and were asked about adverse events. A total of 265 healthy adult volunteers were included from Ethiopia, Oman, and the Czech Republic. The mean plasma concentrations at the 2-h sampling time of each probe drug in the total sample were: 1663 ng/mL for caffeine, 8 ng/mL for bupropion, 789 ng/mL for flurbiprofen, 6 ng/mL for dextromethorphan, 2 ng/mL for midazolam, 35 ng/mL for fexofenadine, and 103 ng/mL for omeprazole. Four adverse events were observed representing an occurrence of 1.5%. All these events were categorized as mild to moderate, non-serious, and resolved spontaneously. A causal link with the cocktail cannot be excluded because of the temporal relationship but is at most evaluated as possible according to the World Health Organization-Uppsala Monitoring Centre causal assessment system. In this research, healthy volunteers from three different human populations were phenotyped with the Geneva cocktail. Four adverse events were observed, confirming the safety of this cocktail that is given at lower than clinically relevant doses and therefore results in concentrations lower than those reported to cause adverse events.

Identifiants

pubmed: 32851583
doi: 10.1007/s40264-020-00983-8
pii: 10.1007/s40264-020-00983-8
pmc: PMC7575470
doi:

Substances chimiques

ATP Binding Cassette Transporter, Subfamily B, Member 1 0
Cytochrome P-450 Enzyme Inhibitors 0
Drug Combinations 0
Pharmaceutical Preparations 0
Cytochrome P-450 Enzyme System 9035-51-2

Banques de données

ClinicalTrials.gov
['NCT02789527']

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1181-1189

Références

Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci. 2005;360(1460):1563–70.
doi: 10.1098/rstb.2005.1685
Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392(6):1093–108.
doi: 10.1007/s00216-008-2291-6
Elewa H, Wilby KJ. A review of pharmacogenetics of antimalarials and associated clinical implications. Eur J Drug Metab Pharmacokinet. 2017;42(5):745–56.
doi: 10.1007/s13318-016-0399-1
Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit. 2004;26(2):180–5.
doi: 10.1097/00007691-200404000-00017
de Andrés F, Lerena LA. Simultaneous determination of cytochrome P450 oxidation capacity in humans: a review on the phenotyping cocktail approach. Curr Pharm Biotechnol. 2016;17(13):1159–80.
doi: 10.2174/1389201017666160926150117
Bosilkovska M, Samer C, Déglon J, Thomas A, Walder B, Desmeules J, et al. Evaluation of mutual drug-drug interaction within Geneva cocktail for cytochrome P450 phenotyping using innovative dried blood sampling method. Basic Clin Pharmacol Toxicol. 2016;119(3):284–90.
doi: 10.1111/bcpt.12586
Bosilkovska M, Samer CF, Déglon J, Rebsamen M, Staub C, Dayer P, et al. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther. 2014;96(3):349–59.
doi: 10.1038/clpt.2014.83
The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf . Accessed 29 Apr 2020.
Bosilkovska M, Clément M, Dayer P, Desmeules J, Daali Y. Incorporation of flurbiprofen in a 4-drug cytochrome p450 phenotyping cocktail. Basic Clin Pharmacol Toxicol. 2014;115(5):465–6.
doi: 10.1111/bcpt.12231
Lloret-Linares C, Bosilkovska M, Daali Y, Gex-Fabry M, Heron K, Bancila V, et al. Phenotypic assessment of drug metabolic pathways and P-glycoprotein in patients treated with antidepressants in an ambulatory setting. J Clin Psychiatry. 2018;79(2):16m11387.
doi: 10.4088/JCP.16m11387
Lloret-Linares C, Rollason V, Lorenzini KI, Samer C, Daali Y, Gex-Fabry M, et al. Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study. Pharmacol Res. 2017;118:104–10.
doi: 10.1016/j.phrs.2016.07.002
Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017;109(Pt 1):585–648.
doi: 10.1016/j.fct.2017.04.002
Kuate C, Gélisse P, Baldy-Moulinier M, Crespel A. Bupropion-induced epileptic seizures. Rev Neurol (Paris). 2004;160(6–7):701–3.
doi: 10.1016/S0035-3787(04)71021-8
Goren JL, Levin GM. Mania with bupropion: a dose-related phenomenon? Ann Pharmacother. 2000;34(5):619–21.
doi: 10.1345/aph.19313
Laib AK, Brünen S, Pfeifer P, Vincent P, Hiemke C. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion. Ther Drug Monit. 2014;36(4):473–9.
doi: 10.1097/FTD.0000000000000042
Hamdy RC, Bird A, Le Gallez P, Hill J, Hind ID. A multiple dose pharmacokinetic and tolerance study of once daily 200 mg sustained-release flurbiprofen capsules in young and very elderly patients. Eur J Clin Pharmacol. 1990;39(3):267–70.
doi: 10.1007/BF00315108
Siu A, Drachtman R. Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain. CNS Drug Rev. 2007;13(1):96–106.
doi: 10.1111/j.1527-3458.2007.00006.x
Franken LG, de Winter BCM, Masman AD, van Dijk M, Baar FPM, Tibboel D, et al. Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. Br J Clin Pharmacol. 2018;84(2):320–30.
doi: 10.1111/bcp.13442
Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther. 1992;51(6):715–28.
doi: 10.1038/clpt.1992.84
Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol. 2003;112(4 Suppl.):S69–77.
doi: 10.1016/S0091-6749(03)01879-7
Smith SM, Gums JG. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009;5(7):813–22.
doi: 10.1517/17425250903044967
Forgerini M, Mieli S, de Mastroianni PC. Safety assessment of omeprazole use: a review. Sao Paulo Med J. 2018;136(6):557–70.
doi: 10.1590/1516-3180.2018.0019220318
Clissold SP, Campoli-Richards DM. Omeprazole: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs. 1986;32(1):15–47.
doi: 10.2165/00003495-198632010-00002

Auteurs

Victoria Rollason (V)

Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals and University of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva, Switzerland. Victoria.Rollason@hcuge.ch.

Médéric Mouterde (M)

Department of Genetics and Evolution (GENEV), Anthropology Unit, University of Geneva, 30, Quai Ernest-Ansermet, 1205 Geneva, Switzerland. Mederic.Mouterde@unige.ch.

Youssef Daali (Y)

Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals and University of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva, Switzerland.

Martina Čížková (M)

Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic.

Edita Priehodová (E)

Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic.

Iva Kulichová (I)

Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic.

Helena Posová (H)

Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Jitka Petanová (J)

Institute of Immunology and Microbiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Anwar Mulugeta (A)

Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Eyasu Makonnen (E)

Department of Pharmacology and Clinical Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Abir Al-Habsi (A)

Oman Specialty Board, Muscat, Sultanate of Oman.

Robin Davidson (R)

Department of Family Medicine, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.

Khalid K Al-Balushi (KK)

Department of Pharmacology and Clinical Pharmacy, Sultan Qaboos University, Muscat, Sultanate of Oman.

Khalid Al-Thihli (K)

Department of Genetics, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.

Marie Cerná (M)

Department of Medical Genetics, Third Faculty of Medicine, Charles University, Prague, Czech Republic.

Said Al-Yahyaee (S)

Department of Genetics, College of Medicine and Health Sciences, Muscat, Sultanate of Oman.

Viktor Černý (V)

Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic.

Getnet Yimer (G)

Global One Health Initiative, Office of International Affairs, The Ohio State University, Columbus, OH, USA.

Estella S Poloni (ES)

Department of Genetics and Evolution (GENEV), Anthropology Unit, University of Geneva, 30, Quai Ernest-Ansermet, 1205 Geneva, Switzerland.
Institute of Genetics and Genomics of Geneva (iGE3), Geneva, Switzerland.

Jules Desmeules (J)

Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals and University of Geneva, Rue Gabrielle-Perret-Gentil 4, 1211, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH